Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURPASS-4: tirzepatide once weekly versus insulin glargine in type 2 diabetes with increased cardiovascular risk
MOH_2019-02-19_005980Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tirzepatide and insulin glargine in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Started Dec 2018; status: completed.
02
Drugs
tirzepatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2019-02-19_005980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-19_005980.